US 12,109,241 B2Granted

Methods of manufacture of immunocompatible chorionic membrane products

AssigneeOsiris Therapeutics, Inc.

InventorsSamson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi

Life of this patent

Estimating the term…

Loading patent…

Abstract

Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Claims19

Dependent claims

A method of treating a skin and/or dermal tissue injury of a subject, the method comprising administering to the skin and/or dermal tissue injury of the subject a cryopreserved portion of a placenta,

wherein the cryopreserved placental portion comprises at least 70% viable therapeutic cells native to the placental portion,
wherein the cryopreserved placental portion is substantially depleted of immunogenic cells comprising trophoblasts, functional CD14+ macrophages, or both trophoblasts and functional CD14+ macrophages, and
wherein the cryopreserved placental portion comprises a chorionic membrane of the placenta or the cryopreserved placental portion has a thickness of about 40 μm to about 400 μm.

Dependencies are inferred from the claim text.

Facts

Application: 18/094,148Filed 6 Jan 2023 · continuation
Priority: 18 Feb 2010
Published: US 2023/0381241 A130 Nov 2023
Granted: 8 Oct 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61K 35/28
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically…:…
A01N 1/125
Preservation or perfusion media: freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
A61K 35/50
Reproductive organs: placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
A61K 38/1825
Growth factors; Growth regulators: fibroblast growth factor [FGF]

Family

Application61/338,489Us provisional application · filed 18 Feb 2010
Application61/338,464Us provisional application · filed 18 Feb 2010
Application61/369,562Us provisional application · filed 30 Jul 2010
Application13/030,539Parent of this continuation · filed 18 Feb 2011
Application14/069,894Parent of this continuation · filed 1 Nov 2013
Application16/271,038Parent of this continuation · filed 8 Feb 2019
US 10,258,650 B2Parent of this continuation · filed 16 Apr 2019
US 2023/0381241 A1Pre-grant publication · published 30 Nov 2023
US 11,638,725 B2Parent of this continuation
US 2011/0212063 A1Published application
US 2014/0140966 A1Published application
US 2020/0330520 A1Published application
US 12,109,241 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key